Produktinformation
Mizagliflozin is an experimental drug that inhibits sodium-dependent glucose uptake in the intestine. It is being developed for use in the treatment of type 2 diabetes and obesity. Mizagliflozin has been shown to reduce blood sugar levels, body weight, and insulin resistance in rats with diet-induced obesity. The drug has been found to be well tolerated in clinical trials so far. Mizagliflozin does not cause hypoglycemia or increase the risk of heart attack or stroke. Mizagliflozin has a low potential for abuse and is not addictive. This drug also does not cause constipation like other common antidiabetic drugs.
Mizagliflozin has been shown to work by binding to tyrosine phosphatases (TP), which are enzymes that regulate cellular processes such as cell growth, differentiation, and motility. This binding prevents TP from dephosphorylating phosphotyrosine residues on proteins such as insulin receptor substrate 1
Chemische Eigenschaften
Technische Anfrage zu: 3D-RBB84310 Mizagliflozin
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.
